On this news, Bristol-Myers's share price fell $12.04, or 16%, to close at $63.28 on August 5, 2016. The Company's …
Bristol-Myers Squibb Co. was slapped with a putative class action in California federal court on Friday, alleging company officials deceived investors about the prospects for its lung cancer drug, which resulted in artificially inflated company …
This morning the Bay Area-based company forged a new collaboration with pharma giant Bristol-Myers Squibb to develop and commercialize ... the acquisition of more than 8 million shares of common stock. Additionally, Nektar will be …
Bristol Myers Squibb's ( BMY) stock has had an eventful few years. It has largely fluctuated depending on how its key oncology drugs have done in clinical trials, and the company's near- and intermediate-term outlook will primarily depend …
NASDAQ2mon
On the one hand, fundamentally BMY is not expensive relative to its peers from a price-to-earnings perspective. It also has a decent balance sheet and runs respectable net margins so there aren’t any obvious issues. But on the other hand, …
Bristol-Myers Squibb (NYSE: BMY), in many ways, has led the immuno-oncology revolution with its game-changing checkpoint inhibitors Opdivo and Yervoy. However, the stock has lost a bit of its shine in the past year, thanks to …
Shares of Bristol-Myers Squibb Co. (ticker: BMY) fell more than 16 percent Friday after the company announced that its Opdivo drug failed a study that would have expanded its use to lung cancer patients. BMY stock dropped more than …